Detalles de la búsqueda
1.
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
Int J Cancer
; 154(10): 1760-1771, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38296842
2.
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Cancer
; 130(9): 1673-1683, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38198485
3.
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
Int J Cancer
; 152(12): 2493-2502, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36843274
4.
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
Cancer Immunol Immunother
; 72(12): 4049-4064, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37794264
5.
Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
Cancer
; 128(14): 2746-2752, 2022 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35439334
6.
Physical activity and checkpoint inhibition: association with toxicity and survival.
J Natl Cancer Inst
; 116(4): 573-579, 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001030
7.
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance.
NPJ Precis Oncol
; 7(1): 41, 2023 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37173424
8.
Prognostic value of Lynch syndrome, BRAFV600E , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.
Cancer Med
; 12(15): 15841-15853, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37326121
9.
Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis.
iScience
; 26(10): 107891, 2023 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37766980
10.
Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice.
J Pain Symptom Manage
; 63(6): 997-1005, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35196557
11.
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
JAMA Oncol
; 8(12): 1794-1801, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36301521
12.
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review.
Front Oncol
; 10: 585311, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33643899
13.
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
ESMO Open
; 5(6): e000945, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33199288
14.
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.
Clin Cancer Res
; 26(9): 2268-2274, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31988197
15.
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events-Reply.
JAMA Oncol
; 9(5): 724, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36892850
16.
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out.
Nat Rev Rheumatol
; 17(8): 505, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34103723
17.
Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors.
JAMA Oncol
; 6(8): 1300-1301, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32556062
Resultados
1 -
17
de 17
1
Próxima >
>>